Price Change to Note: Is Buying Stock Like Global Blood Therapeutics Inc After Such Increase Winning Strategy?

Price Change to Note: Is Buying Stock Like Global Blood Therapeutics Inc After Such Increase Winning Strategy?

The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! The stock increased 4.80% or $0.85 during the last trading session, hitting $18.55. About 175,562 shares traded hands. Global Blood Therapeutics Inc (NASDAQ:GBT) has declined 16.86% since April 22, 2016 and is downtrending. It has underperformed by 22.27% the S&P500.
The move comes after 7 months positive chart setup for the $714.42 million company. It was reported on Nov, 25 by Barchart.com. We have $19.66 PT which if reached, will make NASDAQ:GBT worth $42.87M more.

Analysts await Global Blood Therapeutics Inc (NASDAQ:GBT) to report earnings on April, 4. They expect $-0.65 EPS, down 22.64% or $0.12 from last year’s $-0.53 per share. After $-0.58 actual EPS reported by Global Blood Therapeutics Inc for the previous quarter, Wall Street now forecasts 12.07% negative EPS growth.

Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage

Out of 4 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Global Blood Therapeutics has been the topic of 7 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The company was initiated on Tuesday, September 8 by Morgan Stanley. Empire maintained the stock with “Buy” rating in Friday, June 17 report. As per Tuesday, September 8, the company rating was initiated by Wedbush. The company was initiated on Tuesday, September 8 by Goldman Sachs. On Tuesday, October 25 the stock rating was maintained by Wedbush with “Outperform”. The firm earned “Outperform” rating on Tuesday, September 8 by Cowen & Co.

According to Zacks Investment Research, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.”

More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: Fool.com which released: “Why Global Blood Therapeutics Inc.’s Shares Are Soaring Today” on October 25, 2016, also Wsj.com with their article: “Global Blood Therapeutics Shares Jump After Positive Results for Pivotal Drug” published on June 10, 2016, Prnewswire.com published: “Global Blood Therapeutics Announces Appointment of Jeffrey Farrow as CFO” on April 04, 2016. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: Prnewswire.com and their article: “Global Blood Therapeutics Announces Initiation of Phase 2a Study of GBT440 in …” published on June 29, 2016 as well as Benzinga.com‘s news article titled: “Global Blood Therapeutics Reaches Agreement With FDA On Sickle Cell Disease …” with publication date: October 24, 2016.

GBT Company Profile

Global Blood Therapeutics, Inc., incorporated on February 04, 2011, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Firm is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). HAE is a rare, genetic disorder characterized by severe and potentially life-threatening systemic inflammation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment